Skip to main content
Amit Anand, MD, Psychiatry, Boston, MA

AmitAnandMD

Psychiatry Boston, MA

Professor, Harvard Medical School. Mass General Brigham.

Dr. Anand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Anand's full profile

Already have an account?

  • Office

    221 Longwood Ave
    Boston, MA 02115

Summary

  • Dr. Anand is Professor of Psychiatry at Harvard Medical School and Director of Translational Clinical Trials at Mass General Brigham. Dr. Anand completed his training from the All India Institute of Medical Sciences, the RANZCP and Yale University. He has conducted the first studies of use of ketamine and glutamatergic modulation and resting state brain connectivity in mood disorders.

Education & Training

  • Griffin Hospital
    Griffin HospitalResidency, Internal Medicine, 1994 - 1994
  • Yale-New Haven Hospital
    Yale-New Haven HospitalFellowship, Clinical Neuroscience, 1992 - 1994
  • Royal Australian and New Zealand College of Psychiatrists
    Royal Australian and New Zealand College of PsychiatristsFRANZCP, Psychiatry, 1986 - 1991
  • All India Institute of Medical Sciences
    All India Institute of Medical SciencesClass of 1985

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2021 - 2026
  • OH State Medical License
    OH State Medical License 2012 - 2025
  • IN State Medical License
    IN State Medical License 2001 - 2017
  • CT State Medical License
    CT State Medical License 1993 - 2007
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • The High Price of Ignoring Disease in the MarginalizedJuly 2020
  • The High Price of Ignoring Disease in the MarginalizedJuly 2020

Press Mentions

  • Ketamine Shows Promise for Hard-to-Treat Depression in New Study
    Ketamine Shows Promise for Hard-to-Treat Depression in New StudyMay 26th, 2023
  • Ketamine Beats Shock Therapy in Easing Tough-to-Treat Depression
    Ketamine Beats Shock Therapy in Easing Tough-to-Treat DepressionMay 25th, 2023
  • Ketamine as Effective as Electroconvulsive Therapy for Treatment-Resistant Depression
    Ketamine as Effective as Electroconvulsive Therapy for Treatment-Resistant DepressionMay 25th, 2023
  • Join now to see all